Van beleggers
voor beleggers
desktop iconMarkt Monitor

Inloggen

  • Geen account? Registreren

Wachtwoord vergeten?

Tonix Pharmaceuticals (TNXP)

11 Posts
| Omlaag ↓
  1. [verwijderd] 11 juli 2014 18:46
    Ik was al een draadje gestart Doewap ;)

    Officers and directors agreed not to sell any common stocks for a period of 90 days from now.

    Ze hebben nu wel erg veel knaken, waarom op dit moment een emissie ?
    Tegen het licht van bovenstaande verwachten ze geen verlaging van de koers (slechte resultaten) dus meer verwatering wanneer ze dan pas een emissie zouden doorvoeren..

    Meer aandelen zijn wel nodig om meer investeerders te kunnen trekken maar toch..
  2. veer62 29 mei 2016 19:36
    B)
    Trading Date Type Shares Traded Price Shares Held
    11 May 2016 Buy 31,042 $2.30 380,724
    10 May 2016 Buy 8,210 $2.24 349,682
    15 Mar 2016 Buy 75,000 $2.29 341,472
    25 Aug 2015 Buy 10,000 $6.05 260,472
    24 Aug 2015 Buy 1,468 $6.40 250,472
    23 Aug 2015 Buy 2,532 $6.20 249,004
    19 Aug 2015 Buy 6,000 $6.64 246,472
    16 Aug 2015 Buy 15,000 $6.93 240,472
    16 Jul 2015 Buy 25,000 $7.50 225,472
    5 Mar 2015 Buy 4,000 $6.57 200,472
    8 Feb 2015 Buy 30,000 $5.85 196,472
    17 Dec 2014 Buy 30,000 $4.25 166,472
    28 Sep 2014 Buy 10,000 $4.25 136,472
    25 Aug 2014 Buy 7,05

    Deze meneer ziet het wel zitten Mario (Ernest B).
  3. forum rang 10 DeZwarteRidder 7 december 2018 15:19
    Tonix Pharmaceuticals stock nearly doubles after filing for upsized equity offering
    07:40 07 Dec 2018

    Investors expect the proceeds to fund new late-stage study of lead drug candidate Tonmya for the treatment of PTSD
    A man looking at a prescription bottle
    The RECOVERY trial evaluating Tonmya for treating PTSD is likely to start in early 2019

    Shares in Tonix Pharmaceuticals (NASDAQ:TNXP) nearly doubled in the pre-market Friday on the heels of a preliminary prospectus for a public offering as the clinical-stage biotech prepares for a new Phase 3 clinical trial, RECOVERY, evaluating Tonmya for the treatment of posttraumatic stress disorder (PTSD).

    In the company’s filing on Thursday it indicated that 2,132,701 Class A units and 9,000 Class B units would be part of its public offering. Each Class A unit would consist of one share of common stock and one warrant to purchase one common share at 125% of the Class A unit price.

    Each Class B unit consists of one Series A preferred share valued at $1,000 and one warrant to purchase 237 common shares.
    READ: Tonix Pharmaceuticals shares rocket after FDA green-lights design of new late-stage study of Tonmya for PTSD

    “Our lead product candidate, Tonmya, or TNX-102 SL, a proprietary low-dose cyclobenzaprine, or CBP, sublingual tablet, designed for bedtime administration, is in Phase 3 development as a potential treatment for PTSD and designated by the US Food and Drug Administration, or FDA, as a Breakthrough Therapy,” the company said in its filing.

    Most significantly, the company reiterated in the filing that it planned to “start the Phase 3 RECOVERY trial of Tonmya 5.6 mg for the treatment of PTSD in the first quarter of 2019.”

    The new trial will incorporate several new design features including restricting enrollment of study participants to individuals with PTSD who experienced an index trauma within nine years of screening, instead of 2001 or later as in the earlier Phase 3 HONOR study.

    The RECOVERY study will also include participants who have experienced civilian traumas in addition to those with military-related traumas.

    The primary endpoint will be the mean change from baseline in the severity of PTSD symptoms as measured by a scale called CAPS-5.

    Tonix Pharmaceuticals CEO Seth Lederman earlier said the compnay was moving forward "expeditiously" to initiate the RECOVERY study and expected "to have topline data in the first half of 2020.”

    The New York-based company said Tonmya has been conditionally accepted by the FDA as the proposed trade name for TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for the treatment of PTSD.
  4. forum rang 4 nb 4 februari 2021 20:49
    quote:

    Galafanaat schreef op 4 februari 2021 14:27:


    Verbazingwekkend weinig belangstelling voor dit aandeel op IEX?

    Veel in de pijplijn dit jaar. Voorbeurs vandaag +25%. Succes allen!

    Vrij logisch met zo'n track record. Maar bedankt voor het onder de aandacht brengen. Inderdaad veel fase 3 en 2.ik waag een gokje. Iets laat nu vandaag, gak 1.34.
11 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Indices

AEX 754,31 -0,50%
EUR/USD 1,1869 0,00%
Germany30^ 15.549,40 -0,58%
Gold spot 1.814,01 0,00%
LONDEN-FTSE 100 7.032,30 -0,65%
NY-Nasdaq Composite 14.672,68 -0,71%

Stijgers

CM.COM
+2,82%
Brunel
+2,76%
CTP
+1,80%
WDP
+1,74%
Avantium
+1,70%

Dalers

INPOST
-5,82%
Air Fr...
-4,58%
Fugro
-4,23%
UNIBAI...
-3,78%
AMG
-2,95%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links